Logo image of ETON

ETON PHARMACEUTICALS INC (ETON) Stock Fundamental Analysis

NASDAQ:ETON - Nasdaq - US29772L1089 - Common Stock - Currency: USD

14.48  -0.69 (-4.55%)

Fundamental Rating

4

ETON gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. ETON scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ETON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ETON had negative earnings in the past year.
ETON had a positive operating cash flow in the past year.
In the past 5 years ETON always reported negative net income.
In multiple years ETON reported negative operating cash flow during the last 5 years.
ETON Yearly Net Income VS EBIT VS OCF VS FCFETON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

1.2 Ratios

ETON's Return On Assets of -15.29% is fine compared to the rest of the industry. ETON outperforms 67.71% of its industry peers.
With a decent Return On Equity value of -34.30%, ETON is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -15.29%
ROE -34.3%
ROIC N/A
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
ETON Yearly ROA, ROE, ROICETON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

ETON has a Gross Margin of 59.30%. This is in the better half of the industry: ETON outperforms 67.71% of its industry peers.
ETON does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETON Yearly Profit, Operating, Gross MarginsETON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

ETON does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ETON has been increased compared to 1 year ago.
ETON has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ETON has been reduced compared to a year ago.
ETON Yearly Shares OutstandingETON Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ETON Yearly Total Debt VS Total AssetsETON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

An Altman-Z score of 8.84 indicates that ETON is not in any danger for bankruptcy at the moment.
ETON's Altman-Z score of 8.84 is amongst the best of the industry. ETON outperforms 85.94% of its industry peers.
ETON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.84
ROIC/WACCN/A
WACC9.78%
ETON Yearly LT Debt VS Equity VS FCFETON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

ETON has a Current Ratio of 1.51. This is a normal value and indicates that ETON is financially healthy and should not expect problems in meeting its short term obligations.
ETON has a worse Current ratio (1.51) than 69.79% of its industry peers.
A Quick Ratio of 1.41 indicates that ETON should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.41, ETON is doing worse than 64.58% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.41
ETON Yearly Current Assets VS Current LiabilitesETON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ETON have decreased strongly by -400.00% in the last year.
Looking at the last year, ETON shows a small growth in Revenue. The Revenue has grown by 5.63% in the last year.
The Revenue has been growing by 824.84% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.9%

3.2 Future

The Earnings Per Share is expected to grow by 111.89% on average over the next years. This is a very strong growth
ETON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.72% yearly.
EPS Next Y-115.34%
EPS Next 2Y229.24%
EPS Next 3Y187.26%
EPS Next 5Y111.89%
Revenue Next Year18.46%
Revenue Next 2Y57.55%
Revenue Next 3Y60.16%
Revenue Next 5Y48.72%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ETON Yearly Revenue VS EstimatesETON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ETON Yearly EPS VS EstimatesETON Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ETON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 27.30, ETON can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, ETON is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of ETON to the average of the S&P500 Index (22.34), we can say ETON is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 27.3
ETON Price Earnings VS Forward Price EarningsETON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETON Per share dataETON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

ETON's earnings are expected to grow with 187.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y229.24%
EPS Next 3Y187.26%

More info and screens

0

5. Dividend

5.1 Amount

ETON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ETON PHARMACEUTICALS INC

NASDAQ:ETON (3/6/2025, 3:37:52 PM)

14.48

-0.69 (-4.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners49.94%
Inst Owner Change40.76%
Ins Owners5.61%
Ins Owner Change2.48%
Market Cap385.60M
Analysts82.22
Price Target26.18 (80.8%)
Short Float %1.4%
Short Ratio1.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)163.03%
Min EPS beat(2)-68.07%
Max EPS beat(2)394.12%
EPS beat(4)2
Avg EPS beat(4)60.03%
Min EPS beat(4)-120.59%
Max EPS beat(4)394.12%
EPS beat(8)6
Avg EPS beat(8)113.25%
EPS beat(12)7
Avg EPS beat(12)32.9%
EPS beat(16)8
Avg EPS beat(16)20.49%
Revenue beat(2)2
Avg Revenue beat(2)2.75%
Min Revenue beat(2)1.09%
Max Revenue beat(2)4.4%
Revenue beat(4)2
Avg Revenue beat(4)-0.94%
Min Revenue beat(4)-6.89%
Max Revenue beat(4)4.4%
Revenue beat(8)5
Avg Revenue beat(8)11.57%
Revenue beat(12)6
Avg Revenue beat(12)-2.77%
Revenue beat(16)6
Avg Revenue beat(16)-14.15%
PT rev (1m)0%
PT rev (3m)97.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)83.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.41%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.3
P/S 11.12
P/FCF N/A
P/OCF 181.97
P/B 24.13
P/tB 38.08
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)0.53
Fwd EY3.66%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY0.55%
SpS1.3
BVpS0.6
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.29%
ROE -34.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.3%
FCFM N/A
ROA(3y)-15.37%
ROA(5y)-51.94%
ROE(3y)-28.71%
ROE(5y)-87.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 250.19%
Cap/Sales 7.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.41
Altman-Z 8.84
F-Score3
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)317.45%
Cap/Depr(5y)274.23%
Cap/Sales(3y)10.17%
Cap/Sales(5y)69.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-400%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%250%
EPS Next Y-115.34%
EPS Next 2Y229.24%
EPS Next 3Y187.26%
EPS Next 5Y111.89%
Revenue 1Y (TTM)5.63%
Revenue growth 3Y824.84%
Revenue growth 5YN/A
Sales Q2Q%46.9%
Revenue Next Year18.46%
Revenue Next 2Y57.55%
Revenue Next 3Y60.16%
Revenue Next 5Y48.72%
EBIT growth 1Y-259.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.22%
EBIT Next 3Y149.02%
EBIT Next 5YN/A
FCF growth 1Y94.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.48%
OCF growth 3YN/A
OCF growth 5YN/A